| abstract |
Provided are a humanized monoclonal antibody against PcrV or a part thereof, and a pharmaceutical composition containing the same as an active ingredient, as an effective means for therapy of infection, particularly infection with Pseudomonas aeruginosa. Concretely, the humanized monoclonal antibody of the present invention has an excellent inhibitory activity on the cytotoxicity with respect to a target cell of Pseudomonas aeruginosa. Also, the humanized monoclonal antibody of the present invention has a high affinity for PcrV. |